Moderna COVID-19 vaccine
RNA COVID-19 vaccine / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Moderna COVID-19 vaccine?
Summarize this article for a 10 year old
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months,[47] twelve years, or eighteen years and older. It provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus.[41][2][21][14] It is designed to be administered in two or three 0.5-mL doses given by intramuscular injection at an interval of at least 28 days apart.[32][48][49][50]
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Trade names | Spikevax[1][2] |
Other names | mRNA-1273, CX-024414, COVID-19 mRNA Vaccine Moderna, TAK-919, Moderna COVID‑19 Vaccine, COVID‑19 Vaccine Moderna, COVID-19 Vaccine Moderna Intramuscular Injection,[3] elasomeran,[4][5] COVID-19 Vaccine (mRNA),[6] davesomeran,[4] imelasomeran,[4] andusomeran,[4] CX-034476, CX-038839 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a621002 |
License data | |
Pregnancy category | |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
ChEMBL |
It is an mRNA vaccine composed of nucleoside-modified mRNA (modRNA) encoding a spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles.[51]
It is authorized for use at some level in many countries.[52][53][54][55]
In August and September 2022, bivalent versions of the vaccine (Moderna COVID-19 Vaccine, Bivalent) containing elasomeran/elasomeran 0-omicron (Spikevax Bivalent Zero/Omicron)[56] were authorized for use as booster doses in individuals aged 18 years of age or older in the United Kingdom,[57][58] Switzerland,[59] Australia,[60] Canada,[61][62] the European Union,[2] and the United States.[63][64] The second component of the version of the bivalent vaccine used in the United States (mRNA-1273.222[65]) is based on the Omicron BA.4/BA.5 variant,[63] while the second component of the bivalent vaccine version used in other countries (mRNA-1273.214) is based on the Omicron BA.1 variant.[2][56][58][57][62]